ConnectiCare

Commercial/Healthcare Exchange PA Criteria

Effective: August 14th, 2019

Prior Authorization: Sunosi

Products Affected: Sunosi (solriamfetol) tablet

Medication Description: Solriamfetol is a dopamine and norepinephrine reuptake inhibitor (DNRI) indicated to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (OSA).

Covered Uses:

1. Excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (OSA).

Exclusion Criteria: Concurrent treatment with a monoamine oxidase inhibitor (MAOI) or use of an MAOI within the preceding 14 days.

Required Medical Information:

1. Diagnosis
2. Previous therapies tried and failed

Age Restrictions: 18 years of age or older

Prescriber Restrictions: Prescribed by or in consultation with a sleep disorder specialist, psychiatrist, or neurologist

Coverage Duration: 12 months

Other Criteria:

Excessive daytime sleepiness associated with narcolepsy

A. Patient has a diagnosis of excessive daytime sleepiness associated with narcolepsy; **AND**
B. Patient must have a trial and failure, contraindication, or intolerance to one CNS stimulant drug (e.g., methylphenidate, dexmethylphenidate, dextroamphetamine) AND one CNS wakefulness promoting drug (e.g. armodafinil).

Excessive daytime sleepiness associated with obstructive sleep apnea (OSA)

A. Patient has a diagnosis of excessive daytime sleepiness associated with obstructive sleep apnea (OSA); **AND**
B. Patient's underlying airway obstruction has been treated (e.g., with continuous positive airway pressure (CPAP)) for at least one month prior to initiating Sunosi; **AND**
C. Sunosi will be used in conjunction with continuous positive airway pressure (CPAP); **OR**
D. The patient is unable to initiate or tolerate CPAP therapy; **AND**
E. Patient must have a trial and failure, contraindication, or intolerance to armodafinil or modafinil.

References:

1. Sunosi™ tablets [prescribing information]. Palo Alto, CA: Jazz Pharmaceuticals, Inc.; March 2019.
2. National Institutes of Health. Narcolepsy Fact Sheet. National Institute of Neurological Disorders and Stroke. Date last modified: July, 6, 2018. Available at: https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Narcolepsy-Fact-Sheet. Accessed on July 31, 2019.

3. Mayo Clinic. Obstructive sleep apnea. Available at: https://www.mayoclinic.org/diseases-conditions/obstructive-sleep-apnea/symptoms-causes/syc-20352090?p=1. Accessed on July 31, 2019.
4. Provigil® tablets [prescribing information]. North Wales, PA: Teva Pharmaceuticals USA, Inc.; November 2018.
5. Nuvigil® tablets [prescribing information]. North Wales, PA: Teva Pharmaceuticals USA, Inc.; November 2018.
6. Szabo ST, Thorpy MJ, Mayer G, et al. Neurobiological and immunogenetic aspects of narcolepsy: implications for pharmacotherapy. *Sleep Med Rev*. 2019;43:23-36.

Policy Revision history

Rev #	Type of Change	Summary of Change	Sections Affected	Date
1	New Policy	New Policy	All	08/12/2019